Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease

The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients wi...

Full description

Bibliographic Details
Main Authors: Deniz Tuncel, Fatma Inanc Tolun, Ismail Toru
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2009/132464
id doaj-d6550d7e82e94486ad37df400641d339
record_format Article
spelling doaj-d6550d7e82e94486ad37df400641d3392020-11-24T22:27:51ZengHindawi LimitedMediators of Inflammation0962-93511466-18612009-01-01200910.1155/2009/132464132464Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's DiseaseDeniz Tuncel0Fatma Inanc Tolun1Ismail Toru2Department of Neurology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyDepartment of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyDepartment of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, TurkeyThe aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3±0.4 𝜇mol/L) was significantly lower than that in the control group (2.8±0.6 𝜇mol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results.http://dx.doi.org/10.1155/2009/132464
collection DOAJ
language English
format Article
sources DOAJ
author Deniz Tuncel
Fatma Inanc Tolun
Ismail Toru
spellingShingle Deniz Tuncel
Fatma Inanc Tolun
Ismail Toru
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
Mediators of Inflammation
author_facet Deniz Tuncel
Fatma Inanc Tolun
Ismail Toru
author_sort Deniz Tuncel
title Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
title_short Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
title_full Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
title_fullStr Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
title_full_unstemmed Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
title_sort serum insulin-like growth factor-1 and nitric oxide levels in parkinson's disease
publisher Hindawi Limited
series Mediators of Inflammation
issn 0962-9351
1466-1861
publishDate 2009-01-01
description The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3±0.4 𝜇mol/L) was significantly lower than that in the control group (2.8±0.6 𝜇mol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results.
url http://dx.doi.org/10.1155/2009/132464
work_keys_str_mv AT deniztuncel seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease
AT fatmainanctolun seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease
AT ismailtoru seruminsulinlikegrowthfactor1andnitricoxidelevelsinparkinsonsdisease
_version_ 1725748724735410176